Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Enveric BiosciencesENVB +1.04%30 3-Year EPS without NRI Growth Rate is 75.10% as of Jun. 2026, which is 7% above its 10-year median of 69.90. GuruFocus rates ENVB with a GF Score™ of 30/100. The stock has 1 warning sign investors should review. Among 1,160 Biotechnology companies, Enveric Biosciences ranks better than 94.31% on this metric.
During the past 3 years, the average EPS without NRI Growth Rate was 75.10% per year.
During the past 5 years, the average EPS without NRI Growth Rate was 65.30% per year.
During the past 10 years, the average EPS without NRI Growth Rate was 57.60% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Enveric Biosciences was 77.80% per year. The lowest was -87.80% per year. And the median was 69.90% per year.
Enveric Biosciences (NAS:ENVB) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Enveric Biosciences 3-Year EPS without NRI Growth Rate Related Terms
ENVB vs ACXP, HCWB, AAGH: 3-Year EPS without NRI Growth Rate Comparison
For the Biotechnology subindustry, Enveric Biosciences's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Enveric Biosciences 3-Year EPS without NRI Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Enveric Biosciences's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Enveric Biosciences's 3-Year EPS without NRI Growth Rate falls into.
Enveric Biosciences 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 75.10% mean?
Enveric Biosciences (ENVB) has a 3-Year EPS without NRI Growth Rate of 75.10% as of Jun. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Enveric Biosciences and its competitors. This is near median its historical median of 69.90. According to the industry distribution chart, Enveric Biosciences ranks #66 out of 1160 companies in the Biotechnology industry, placing it in the top 5.7%.
Is Enveric Biosciences' 3-Year EPS without NRI Growth Rate too high?
Enveric Biosciences' current 3-Year EPS without NRI Growth Rate of 75.10% is near median its 10-year median of 69.90. The Biotechnology industry median 3-Year EPS without NRI Growth Rate is 16.05. Enveric Biosciences' value of 75.10% is 367.9% above this industry median. Based on the distribution chart, Enveric Biosciences ranks #66 out of 1160 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Enveric Biosciences has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Enveric Biosciences' 3-Year EPS without NRI Growth Rate compare to ACXP and HCWB?
According to the Biotechnology industry distribution chart, Enveric Biosciences ranks #66 out of 1160 companies for 3-Year EPS without NRI Growth Rate. This places Enveric Biosciences in the top 6% of its industry — outperforming the majority of peers. The industry median 3-Year EPS without NRI Growth Rate is 16.05. Enveric Biosciences' value of 75.10% is 367.9% above this benchmark. While the company's 10-year median is 69.90 vs. the industry median of 16.05, Enveric Biosciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Biotechnology company?
The median 3-Year EPS without NRI Growth Rate among Biotechnology companies is 16.05, based on 1,160 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Enveric Biosciences's current 3-Year EPS without NRI Growth Rate of 75.10% is 367.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Enveric Biosciences and its competitors. For the Biotechnology industry, the median 3-Year EPS without NRI Growth Rate is 16.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Enveric Biosciences's current 3-Year EPS without NRI Growth Rate is 75.10%, which is near median its own 10-year median of 69.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Enveric Biosciences stock overvalued right now?
Enveric Biosciences (ENVB) has a current 3-Year EPS without NRI Growth Rate of 75.10%. The current 3-Year EPS without NRI Growth Rate is 75.10%, which is near median its 10-year median of 69.90 and 367.9% above the Biotechnology industry median of 16.05. Enveric Biosciences' overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Enveric Biosciences (ENVB), the current 3-Year EPS without NRI Growth Rate is 75.10% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.
30GF Score
Get the complete analysis for ENVB
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ENVB has been successfully added to your 
